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Background. Tuberculosis-immune reconstitution inﬂammatory syndrome (TB-IRIS) in patients coinfected
with human immunodeﬁciency virus (HIV) and tuberculosis starting antiretroviral therapy (ART) is associated
with hypercytokinemia. As adjunctive corticosteroid therapy and vitamin D have immunomodulatory properties,
we investigated the relationship between cytokine/chemokine proﬁles, corticosteroid use, and vitamin D deﬁciency
in TB-IRIS patients.
Methods. Plasma from 39 TB-IRIS and 42 non-IRIS patients was collected during a prospective study of
HIV-associated tuberculosis patients starting ART. In total, 26% of patients received corticosteroid (CTC) therapy
pre-ART for severe tuberculosis. Concentrations of total 25-hydroxyvitamin D (25(OH)D) and 14 cytokines/che-
mokines were determined at ART initiation and 2 weeks later.
Results. Patients prescribed concurrent CTC had lower interferon γ (IFN-γ), IP-10, tumor necrosis factor (TNF),
interleukin (IL)-6, IL-8, IL-10, IL-12p40, and IL-18 pre-ART (P≤ .02). TB-IRIS presented at 12 days (median) of ART,
irrespective of CTC use. In patients who developed TB-IRIS (not on CTC) IL-6, IL-8, IL-12p40, IL-18, IP-10, and TNF
increased during 2 weeks (P≤ .04) of ART. Vitamin D deﬁciency (total 25(OH)D <75 nmol/L) was highly prevalent
(89%) at baseline. Although vitamin D deﬁciency at either baseline or 2 weeks was not associated with TB-IRIS, in
those not on CTC the median 25(OH)D decreased during 2 weeks (P = .004) of ART. Severe vitamin D deﬁciency
(total 25(OH)D <25 nmol/L) was associated with higher baseline TNF, IL-6, and IL-8 irrespective of IRIS status.
Conclusions. CTC modiﬁes the inﬂammatory proﬁle of those who develop TB-IRIS. The association between
severe vitamin D deﬁciency and elevated proinﬂammatory cytokines support a study of vitamin D supplementation in
HIV-TB co-infected patients starting ART.
Africa accounts for 82% of the global human immuno-
deﬁciency virus type 1 (HIV-1) associated tuberculosis
burden [1]. Combined antiretroviral therapy (ART) roll-
out has grown steadily, with 54% of HIV-infected tuber-
culosis patients started on ART in South Africa [1].
When HIV-1-infected persons start ART, the resulting
rise in CD4 count and improved immune function par-
tially restore pathogen speciﬁc immunity [2]. However,
8%–43% of patients will experience paradoxical
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deterioration, termed tuberculosis-associated immune recon-
stitution inﬂammatory syndrome (TB-IRIS) [3, 4]. Initiating
ART at lower CD4 count and advanced tuberculosis disease
are the main factors associated with this syndrome [4]. We
have previously shown an association between increased circu-
lating proinﬂammatory cytokines (tumor necrosis factor
[TNF], interleukin [IL]-6, and interferon γ [IFN-γ]) and
TB-IRIS [5]. Corticosteroids (CTC) are antiinﬂammatory
molecules, which have an inhibitory effect on proinﬂamma-
tory T-cells while stimulating antiinﬂammatory and regulatory
T cells [6]. Our randomized placebo-controlled trial of predni-
sone for the treatment of paradoxical TB-IRIS showed reduced
duration of hospitalization and therapeutic procedure numbers,
as well as hastened improvements in TB-IRIS symptoms, and
more rapid reduction in C-reactive protein (CRP) [7].
We also recently showed that vitamin D deﬁciency is highly
prevalent in Cape Town and is associated with active tubercu-
losis in both HIV-uninfected and infected patients, in whom
the association is stronger [8]. Others have shown that patients
with tuberculosis have signiﬁcantly lower 25-hydroxyvitamin
D (25(OH)D) levels than those without in Tanzania and West
Africa [9, 10]. These ﬁndings are supported by the require-
ment of 25(OH)D for activating an IFN-γ mediated antimi-
crobial effector pathway via induction of antimicrobial peptide
synthesis and autophagy in human monocytes and macro-
phages [11], highlighting the importance of adequate amounts
of 25(OH)D for sustaining innate and acquired immunity
against infections. In vitro, 1,25-dihydroxyvitamin D has
also been shown to inhibit leukocyte secretion of IL-6,
IL-12p40, and IFN-γ, while inducing IL-10 [12–14] and
regulatory T-cell polarisation [15], suggesting that one of
its primary roles is to prevent chronic inﬂammation and limit
immunopathology.
As TB-IRIS has been associated with hypercytokinemia and
both HIV and tuberculosis treatment are known to interfere
with vitamin D metabolism [16, 17], we hypothesised that
vitamin D deﬁciency may be associated with TB-IRIS develop-
ment. We therefore assessed the prevalence of vitamin D deﬁ-
ciency in a cohort of HIV-1 and tuberculosis coinfected
patients in Cape Town and investigated the relationship
between 25(OH)D and plasma cytokines/chemokines and TB-
IRIS development, in patients stratiﬁed by CTC use.
MATERIALS AND METHODS
Study Population
HIV-1-tuberculosis coinfected patients admitted to Brooklyn
Chest Hospital (Cape Town, South Africa) for severe tubercu-
losis, started ART while on tuberculosis treatment in the ward
between June 2009 and December 2010. All were inpatients
and monitored closely for 12 weeks after starting ART for
development of TB-IRIS and gave written informed consent
for inclusion in the study. Patients with available plasma at
both baseline and week 2 of ART (81 of 105 enrolled) were
included in this study. Our sample was representative of the
entire cohort. The University of Cape Town Research Ethics
Committee approved the study (REC 049/2009).
Deﬁnitions
Tuberculosis diagnosis was based on smear or culture positivi-
ty. Where this was negative or unavailable, diagnosis accord-
ing to World Health Organization (WHO) guidelines for
smear-negative or extrapulmonary tuberculosis in HIV-1-
infected persons [18]. TB-IRIS was diagnosed according to a
published case deﬁnition [4]. “Non-IRIS” patients were IRIS-
free during the 3-month follow-up period. Severe vitamin D
deﬁciency was deﬁned as total 25(OH)D ≤25 nmol/L, moder-
ate as 25(OH)D between 25 and 50 nmol/L, and suboptimal
as 25(OH)D between 50 and 75 nmol/L [19]. Severe TB-IRIS
was deﬁned by the presence of at least 4/8 symptoms from the
following categories: neurological, pulmonary, abdominal, in-
crease or occurrence of new lymph nodes, presence of effusion
(pulmonary, cardiac, or ascites), occurrence of fever, a heart
rate above 120, and level of CRP above the median of 93 mg/L.
Sampling and Laboratory Assays
Plasma was obtained at the start of ART and 2 weeks postin-
itiation and stored at −80°C for batched analysis. Total plasma
25(OH)D (25(OH)D2 and 25(OH)D3) was measured by radio-
immunoassay (DiaSorin) in duplicate. Quality control was
performed by the vitamin D External Quality Assurance
Survey (DEQAS, www.deqas.org). To assess the association
between vitamin D status and hypercytokinemia, 14 cyto-
kines/chemokines were measured based on our previous
study [5], in 39 IRIS and 38 non-IRIS patients with available
sample. Granulocyte-macrophage colony-stimulating factor
(GM-CSF), IFN-α2, Interferon gamma-induced protein 10 (IP-
10), macrophage inﬂammatory protein (MIP)-1α, MIP-1β,
TNF, IFN-γ, IL-2, IL-6, IL-8, IL-10, IL-12p40, and IL-17 were
quantiﬁed on the Bio-Plex platform (Bio-Rad Laboratories,
Hercules, United States), using customized Milliplex kits
(HCYTMAG-60K, Millipore, Missouri) and IL-18 by enzyme-
linked immunosorbent assay (ELISA; Medical&Biological Lab-
oratories, Japan). Cytokine concentrations below the limit of
detection (LOD) were considered zero.
Statistical Analysis
Statistical analyses were performed using Stata software
(version 10.2; StataCorp, Texas) and GraphPad Prism software
(version 5; GraphPad, San Diego, California). Baseline charac-
teristics, 25(OH)D and cytokine levels were summarized
by count and proportion (%) or median with interquartile
HIV/AIDS • CID 2012:55 (1 October) • 1005
range (IQR). Normality was assessed using graphical proce-
dures. All P values reported were 2-sided at α of 0.05. Differ-
ences between patient groups were assessed by Fisher exact
test for proportions, and Mann-Whitney U test for medians.
Differences in cytokine and 25(OH)D concentrations were
compared using Mann-Whitney U test or Wilcoxon signed
rank test for paired data.
RESULTS
Patient Characteristics
In total, 39 of 81 patients developed IRIS during the longitudi-
nal follow-up at 12 days median (IQR: 7–19) into ART. All
patients were on nonnucleoside reverse transcriptase inhibitor
(NNRTI)-based regimen: an NRTI backbone and either Efa-
virenz (n = 79) or Nevirapine (n = 2). Eight persons in the
IRIS group and 13 in the non-IRIS group were prescribed
adjunctive corticosteroid therapy (CTC) in addition to tuber-
culosis treatment before starting ART (Flow chart, Supple-
mentary Figure 1). No difference was observed between the
IRIS and non-IRIS groups with regard to baseline study vari-
ables (Table 1). Baseline 25(OH)D concentrations were not
different among the 4 seasons.
Effect of Corticosteroids on Baseline Characteristics
CTC were prescribed to tuberculosis patients with life-threat-
ening symptoms (thus severe tuberculosis) for median 33 days
(IQR: 25–38) in TB-IRIS and 41 days (IQR: 26–50) in non-
IRIS (P = .298) before starting ART. The numbers of TB-IRIS
cases in both groups were comparable (CTC: 38.1%, non-
CTC: 51.7%; P = .287). Both groups were also clinically
similar, with the only baseline characteristic signiﬁcantly dif-
ferent being the method of tuberculosis diagnosis: in the CTC
group, more individuals were diagnosed by radiological identi-
ﬁcation (67%) rather than sputum culture (28%) or sputum
smear (5%), compared with the non-CTC group, where diag-
nosis was predominantly by culture (51%) rather than radio-
logical identiﬁcation (37%) or sputum smear (12%), P = .020.
Patients who received CTC pre-ART had signiﬁcantly lower
baseline plasma concentrations of IL-6, IL-8, IL-10, IL-12p40,
IL-18, IFN-γ, IP-10, and TNF (P≤ .016), compared with the
non-CTC group (Table 2). Because of this signiﬁcant effect of
CTC on the cytokine proﬁle of patients, we stratiﬁed the data
by CTC administration in further analyses.
Clinical Manifestation of IRIS in CTC and Non-CTC Groups
Although our study was not designed to analyse the differenc-
es in clinical outcome between the CTC and non-CTC groups,
we noted a trend for patients not on CTC to present with
more severe TB-IRIS clinical presentation, compared with pa-
tients on CTC (10/31, 32% vs 0/8, 0%); P = .082). Non-CTC
TB-IRIS patients also showed a trend for shorter hospitaliza-
tion time after starting ART, compared with those who
received CTC: median, 92 days (IQR, 77–119) vs 130 days
(IQR, 107–146), P = .078.
Plasma Cytokines in TB-IRIS and Non-IRIS
We previously demonstrated an association between increased
cytokine concentrations and TB-IRIS in a cross-sectional
study at week 2 post-ART [5]. We therefore wished to estab-
lish whether differences also existed during ART and deter-
mined the plasma concentration of 14 cytokines/chemokines
before and at 2 weeks of ART.





(n = 42) P b
Male sex 16 (41) 17 (40) .960
Age, years 33.7 (28–42) 33.5 (27–43) .587
Time of sampling .952
January–March 4 (10) 4 (10)
April–June 9 (23) 9 (21)
July–September 17 (44) 20 (48)
September–
December
9 (23) 9 (21)
TB treatment to ARTc
(days)
36 (27–61) 34 (23–56) .809
Viral load
(copies × 104/mL)
67 (20.3–130) 47 (14.5–160) .865
CD4 baseline (cells/mm3) 80 (31–132) 67 (33.5–118) .508
TB diagnosis .942
Radiological 17 (43) 19 (45)
Sputum smear 3 (8) 5 (12)
Cultured AFB/MTB 19 (49) 18 (43)
Type TB .207
PTB 5 (13) 7 (17)
EPTB 6 (15) 11 (26)
PTB + EPTB 28 (72) 24 (57)
WHO stage .584
3 4 (10) 6 (14)
4 35 (90) 36 (86)
Pre-ART hospitalization,d
days
18 (12–26) 14 (11–21) .153
Corticosteroids pre-ART 9 (23) 13 (31) .429
Time on
corticosteroids, days
33 (25–38) 41 (26–50) .298
Abbreviations: AFB, acid fast bacilli; ART, antiretroviral therapy; EPTB,
extrapulmonary tuberculosis; IRIS, immune reconstitution inflammatory
syndrome; MTB, Mycobacterium tuberculosis; PTB, pulmonary tuberculosis;
TB, tuberculosis; WHO, World Health Organization,
a Data are No. (%) or median interquartile range.
b P values determined by Fisher exact test for proportions, and Mann–
Whitney for medians.
c Time between the start of TB treatment and the start of ART.
d Time of hospitalization before starting ART.
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GM-CSF, IL-2, and IL-17 had median concentrations below
the limit of detection and were not included in statistical anal-
yses. Patients not on CTC who developed TB-IRIS showed
higher baseline IFN-γ (P = .050), whereas those who received
CTC and developed TB-IRIS showed higher IL-8 concentra-
tions (P = .037) and a trend toward lower baseline IFN-α2
(P = .054; Figure 1 and Supplementary Table 1). At week 2 of
ART, in the non-CTC group, TNF (P = .003), IFN-γ
(P = .004), IL-6 (P = .008), and IL-8 (P = .014) were signiﬁ-
cantly higher in TB-IRIS patients than non-IRIS. In patients
who received CTC, there were no signiﬁcant differences
between TB-IRIS and non-IRIS (Figure 1).
During the ﬁrst 2 weeks of ART, TB-IRIS patients not on
CTC showed a signiﬁcant increase in IL-6, IL-8, IL-12p40, IL-
18, IP-10, MIP-1β, and TNF (P≤ .036), whereas non-IRIS pa-
tients showed increased MIP-1α (P = .023) and MIP-1β (P
< .001). Conversely, patients on CTC who developed TB-IRIS
showed no signiﬁcant cytokine increase during the 2 weeks of
ART, whereas non-IRIS patients showed signiﬁcantly in-
creased MIP-1β (P = .03) and decreased IL-18 (P = .050,
Figure 1, Supplementary Table 1). Comparing IRIS patients
on CTC with those not on CTC, the increase in TNF, IL-8,
Figure 1. Cytokine concentrations in immune reconstitution inﬂammatory syndrome (IRIS; ﬁlled circles) and non-IRIS (open circles) patients: A–H, not
on CTC (nIRIS = 31, nnonIRIS = 26); I–L, on CTC therapy (nIRIS = 8, nnonIRIS = 12). Line at median. Statistical test: Mann-Whitney (not paired data) and
Wilcoxon signed rank test (paired data); signiﬁcant P values are indicated on the graph. Abbreviations: IFN, interferon; IL, interleukin; IP, inﬂammatory
protein; LOD, limit of detection; MIP, macrophage inﬂammatory protein; TNF, tumor necrosis factor.
Table 2. Baseline Plasma Cytokine (pg/mL) and 25(OH)D
(nmol/L) Concentrations in Patients Who Were on Corticosteroid
Treatment or not on Corticosteroids Before Starting ART
Variablea CTC (n = 21) Non-CTC (n = 56) P b
25(OH)Dc 25.5 (19.0–38.0) 28.2 (21.1–38.7) .360
IFN-α2 47.9 (20.4–74.5) 45.9 (16.8–96.6) .894
IFN-γ 5.8 (1.6–15.2) 19.0 (5.9–45.3) .004
IP-10 3194 (2105–5577) 6328 (4078–11 156) <.001
MIP-1α 0 (0–20.2) 15.7 (0–33.8) .124
MIP-1β 29.7 (19.9–44.2) 32.6 (25.8–55.2) .197
TNF 22.8 (15.2–36.6) 43.7 (30.0–61.5) <.001
IL-6 0 (0–3.6) 5.5 (0–13.8) .005
IL-8 13.8 (8.4–20.5) 22.7 (17.0–45.7) .001
IL-10 9.0 (4.1–15.3) 19.9 (9.0–29.6) .016
IL-12p40 0 (0–3.9) 15.5 (0–37.3) .002
IL-18 1129 (853–1376) 1893 (1447–2834) .003
Abbreviations: CTC, corticosteroid; IFN, interferon; IL, interleukin; IP,
inflammatory protein; MIP, macrophage inflammatory protein; TNF, tumor
necrosis factor.
aData are median interquartile range.
bP values determined by Mann-Whitney test.
cn for 25(OH)D: CTC, n = 21; non-CTC, n = 60.
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and IL-18 during the ﬁrst 2 weeks of ART was more pro-
nounced in patients not on CTC (Supplementary Table 2).
We also compared the difference in cytokine concentrations
between week 2 and baseline (delta change). Patients not on
CTC who developed TB-IRIS had signiﬁcantly increased IL-6,
IL-8, IL-18, and TNF (P≤ .012). Conversely, in patients on
CTC, there was only a trend for decreased IL-10 in patients
who developed TB-IRIS (P = .064).
Relationship of Vitamin D Deﬁciency to TB-IRIS
and Corticosteroid Therapy
Vitamin D deﬁciency was highly prevalent: only 3 of 81 pa-
tients (3.7%) had optimal vitamin D levels (Figure 2). Severe
deﬁciency was observed in 37 of 81 patients (45.7%), moderate
deﬁciency in 35 of 81 patients (43.2%) and the remaining 6 of
81 patients (7.4%) had suboptimal levels of 25(OH)D. CTC
had no effect on baseline vitamin D status (Table 2).
We next analysed plasma 25(OH)D concentrations during
the ﬁrst 2 weeks of ART, stratiﬁed by CTC status (Figure 3).
There was no baseline difference in 25(OH)D between patients
who developed TB-IRIS and those who did not, irrespective of
CTC use. However, 25(OH)D showed a slight, but statistically
signiﬁcant, decrease during the ﬁrst 2 weeks of ART in those
who developed TB-IRIS and did not receive CTC: from 24.7
nmol/L (IQR 19.7–37.2) at day 0 to 22.5 nmol/L (IQR 19.2–
29.0) at 2 weeks, P = .004. At week 2 of ART, 25(OH)D was
signiﬁcantly lower in non-CTC TB-IRIS patients compared to
non-IRIS patients: 22.5 nmol/L (IQR 19.2–29.0) vs 28.0 nmol/L
(IQR 24.0–33.7), P = .026. Consistent with the limited change
in cytokine proﬁle in those who received CTC and developed
TB-IRIS, these patients also had no signiﬁcant change in 25
(OH)D levels at week 2 of ART.
Association Between 25(OH)D Deﬁciency and Plasma Cytokines
Due to the observation that non-CTC TB-IRIS patients
showed a further decrease in 25(OH)D levels during ART and
that these patients had a signiﬁcant increase in the concentra-
tion of a number of cytokines/chemokines at the development
of TB-IRIS, we next investigated if there was an association
between severe vitamin D deﬁciency (<25 nmol/L) and plasma
cytokine/chemokine concentrations in the non-CTC sub-
group. Figure 4A–D shows the 4 cytokines that were associated
with vitamin D status, in non-CTC patients. Patients who
were severely vitamin D deﬁcient had higher concentrations of
IL-8 and IL-18 (P≤ .038) and a trend for higher IL-6
(P = .052) at baseline compared to non–severely deﬁcient
patients, and this difference was maintained at week 2 of ART
for IL-8 (P = .030). There was a signiﬁcant increase in plasma
TNF and IL-8 in the severely vitamin D deﬁcient
patients during 2 weeks of ART (P≤ .039), and a trend for
IL-6 (P = .068). At 2 weeks the number of TB-IRIS patients in
Figure 2. Baseline vitamin D status for all patients (n = 81). Dotted
lines indicate the threshold for severe vitamin D deﬁciency (25(OH)D <25
nmol/L), moderate vitamin D deﬁciency (25(OH)D: 25–50 nmol/L), subop-
timal 25(OH)D levels (25(OH)D: 50–75 nmol/L), and vitamin D sufﬁciency
(25(OH)D >75 nmol/L).
Figure 3. 25(OH)D concentration in patients who developed immune reconstitution inﬂammatory syndrome (IRIS; ﬁlled circles) or did not develop IRIS
(open circles) at baseline and after 2 weeks on antiretroviral therapy (A) in patients who did not receive corticosteroids nIRIS = 31, nnonIRIS = 29 and
(B ) in patients prescribed corticosteroids nIRIS = 8, nnonIRIS = 13. Solid line at median; dotted line indicates severe vitamin D deﬁciency. Statistical test:
Mann-Whitney (unpaired data) and Wilcoxon signed rank test (paired data); signiﬁcant P values are indicated on the graph.
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the severely vitamin D deﬁcient group was proportionally
higher than in the non–severely deﬁcient group (20/27, 74%
vs 10/29, 34.5%, P = .003). Therefore, we conducted the same
analysis focusing on TB-IRIS patients only (Figure 4E–4H, not
on CTC): there was no difference in cytokine levels between
patients with 25(OH)D <25 nmol/L compared to >25 nmol/L,
at both time points. However, IL-6, IL-8, and TNF signiﬁ-
cantly increased during ART in both groups. This suggests
that vitamin D deﬁciency is likely to arise as a consequence of
TB-IRIS, rather than the cause.
DISCUSSION
We conﬁrmed in a longitudinal study that increased circulat-
ing cytokines/chemokines associate with TB-IRIS. We also
report a very high prevalence of vitamin D deﬁciency in our
prospective cohort of hospitalised HIV-1-TB coinfected pa-
tients in Cape Town. Although we found that vitamin D deﬁ-
ciency is not a risk factor for TB-IRIS development, the
patients who develop TB-IRIS and do not receive CTC have a
further reduction in circulating 25(OH)D levels in the ﬁrst 2
weeks of ART, with lower 25(OH)D concentrations compared
to non-IRIS, and a concomitant increase in circulating inﬂam-
matory cytokines/chemokines.
A recent study in HIV-1-infected women showed that 25
(OH)D sufﬁciency protected against all-cause mortality and
HIV-1 disease progression [20]. Only 3.7% patients in our
cohort had sufﬁcient levels of 25(OH)D, comparable to the
ﬁndings described in our recent study on vitamin D in Cape
Town, not including IRIS patients [8]. Even taking into
account a median hospitalisation time of 2 weeks before their
baseline 25(OH)D was measured (which is less than the half-
life of 25(OH)D [21]), suggests that at least 46% of patients
severely deﬁcient at this time, were also deﬁcient upon
hospitalization.
Because we previously demonstrated in a cross-sectional
study that TB-IRIS associates with hypercytokinaemia [5],
here we aimed to conﬁrm this in a longitudinal study and de-
termine when hypercytokinemia arose. As 26% of patients
were on adjunctive CTC therapy for severe tuberculosis before
starting ART, and CTC signiﬁcantly reduced baseline plasma
cytokine levels, we stratiﬁed our data according to CTC use.
We found that 25(OH)D signiﬁcantly decreased during the
ﬁrst 2 weeks of ART in patients not on CTC who developed
TB-IRIS. Although the absolute magnitude of the drop in
25(OH)D was small, it may reﬂect a real biological pheno-
menon. We and others have previously demonstrated a
decrease in 25(OH)D concentrations in HIV-infected persons
Figure 4. Cytokine concentrations stratiﬁed by severe vitamin D deﬁciency (25(OH)D <25 nmol/L, nbaseline = 15 immune reconstitution inﬂammatory
syndrome (IRIS; ﬁlled triangles) and 11 non-IRIS (open triangles), nweek2 = 20 IRIS and 7 non-IRIS) or nonsevere vitamin D deﬁciency (25(OH)D >25 nmol/
L, nbaseline = 15 IRIS and 15 non-IRIS, nweek2 = 10 IRIS and 19 non-IRIS) in patients who did not receive adjunctive corticosteroid therapy. Line at median.
P values determined by Mann-Whitney test for medians. Abbreviations: IL, interleukin; LOD, limit of detection; TNF, tumor necrosis factor.
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on NNRTI-based regimens [22–24]. In the present study, all
patients were on NNRTI-based regimen as well as on tubercu-
losis treatment. The fall in plasma 25(OH)D levels observed in
this study could be partly attributable to the interference of
ART and anti-tuberculosis therapy with vitamin D metabo-
lism [25, 26].
Various explanations have been proposed as to why HIV-
infected persons have lower vitamin D status [27]: (1) in-
creased use of 25(OH)D for maturation and proliferation of T
lymphocytes during HIV infection; and (2) increased cytokine
levels, speciﬁcally TNF, blocking the stimulatory effect of para-
thyroid hormone on the production of the hormonally active
vitamin D (1,25-dihydroxyvitamin D, 1,25(OH)2D). Although
these explanations may account for the drop in 25(OH)D, it is
also possible that ART initiation in a patient who still has
high tuberculosis antigen load, despite starting antituberculo-
sis therapy over activates macrophages and dendritic cells to
produce 1,25(OH)2D locally, stimulated by the reconstituting
T helper cell-produced IFN-γ [11]. Interestingly, baseline
IFN-γ was signiﬁcantly higher in TB-IRIS compared to non-
IRIS patients not on CTC. Increased production of 1,25
(OH)2D will then induce catabolism of 25(OH)D and 1,25
(OH)2D through their catabolising enzyme CYP24A1. This
phenomenon has been used to explain the low 25(OH)D asso-
ciated with granulomatous diseases where activated macro-
phages convert 25(OH)D to 1,25(OH)2D [19]. Conﬁrmation
of this hypothesis would be measuring 1,25(OH)2D and
vitamin catabolites in plasma, resulting from systemic spill-
over, but this was not performed in our study due to limited
sample volume.
We found that TB-IRIS was associated with lower 25(OH)D
and higher cytokine concentrations 2 weeks following ART in
those not receiving CTC and that these differences did not
exist at baseline. The increased concentrations of IL-6, IL-8,
IL-18, and TNF at TB-IRIS presentation are in line with our
previous cross-sectional study [5] and also support the role for
neutrophils (IL-8) and natural killer (NK) cells (IL-18) in the
pathogenesis of IRIS [28]. Moreover, we showed that IL-8 and
IL-18 concentrations were signiﬁcantly higher in severely 25
(OH)D deﬁcient patients at baseline. However, although
Figure 4 shows a correlation between high cytokine levels and
lower vitamin D in the whole cohort, there is no correlation
between severe vitamin D deﬁciency and hypercytokinemia
within TB-IRIS patients. This suggests that the rise in cyto-
kines in TB-IRIS patients is not due to decreased 25(OH)D
after starting ART. In fact, it may be that lower 25(OH)D in
IRIS patients is a consequence of the combination of 25(OH)
D consumption during hypercytokinemia and an interaction
between tuberculosis therapy and ART with vitamin D metab-
olism. Thus, although decreased 25(OH)D may not be the
cause of TB-IRIS, it may contribute to the continued
hyperinﬂammatory response. Indeed, 1,25(OH)2D has been
shown to inhibit neutrophil chemotaxis, degranulation, and
oxidative burst in response to chemokines such as IL-8, via
the complement fragment C5a [29, 30]. Moreover, 1,25
(OH)2D inhibits the production of proinﬂammatory cytokines
via inhibition of intracellular pathways, such as the p38 signal-
ing for IL-6 or the NF-κB complex pathway for IL-8 [31].
Therefore, a continued increase in neutrophil activation and
cytokine production would be seen in absence of sufﬁcient
conversion of 25(OH)D toward 1,25(OH)2D.
Finally, the different immunological proﬁles observed
between those who received corticosteroids compared to those
who did not, suggests there might be different immunological
triggers leading to TB-IRIS development. From all patients re-
ceiving CTC pre-ART, 38% developed TB-IRIS despite de-
creased CTC-induced plasma cytokine concentrations.
Clinically, there was a trend toward less severe clinical manifes-
tation of TB-IRIS in these patients but longer time of hospitali-
zation from the start of ART. The latter could be explained by
the fact that CTC was mainly prescribed to patients requiring
intensive medical care. Future studies should therefore stratify
patients according to CTC use, when investigating immunologi-
cal correlates of IRIS risk and disease manifestation.
In conclusion, we found vitamin D deﬁciency not to be a
risk factor for developing TB-IRIS, but patients developing
TB-IRIS become more severely vitamin D deﬁcient after 2
weeks of ART, while they also develop hypercytokinemia. Due
to an association between IL-6, IL-8, and IL-18 with vitamin
D status at baseline, together with the in vitro evidence of
antiinﬂammatory and the antimycobacterial properties of
vitamin D, the role of 25(OH)D and its active form 1,25
(OH)2D should be further elucidated in TB-IRIS. Future work
should identify what is triggering the reduction in 25(OH)D,
whether this correlates with increased 1,25(OH)2D and
whether 25(OH)D reduction occurs before or after hypercyto-
kinemia and the onset of IRIS symptoms. An approach would
be to supplement patients with vitamin D prior to initiation
of ART and to determine if this decreases TB-IRIS incidence.
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